Agentic Workflow for Scaffold Hopping and Molecular Optimization

Manual scaffold hopping and analog design is a sequential, chemist-intensive bottleneck. This workflow automates the systematic exploration of chemical space using graph-based transformations, fragment libraries, and predictive models to generate thousands of viable analogs in hours. By orchestrating generation, novelty checks, and multi-parameter scoring, it enables parallel exploration of multiple series, compressing months of ideation into weeks and allowing teams to converge on optimal leads faster.

Up to half of synthesized analogs fail due to poor predicted properties or impractical routes. The workflow embeds synthesizability scoring and retrosynthesis planning agents that check reagent availability and route complexity against internal inventory and cost constraints. By front-loading feasibility analysis, it grounds virtual designs in practical chemistry, preventing the synthesis of unrealistic targets and focusing lab resources on high-confidence, high-value molecules.

Manual patent analysis is reactive and slow, risking inadvertent infringement. Integrated agents continuously mine global patent corpora, extract chemical structures and claims, and map them against generated analogs in real-time. This automated IP risk assessment flags infringing regions of chemical space and highlights white space for novel design, enabling proactive steering of chemistry to create stronger, more defensible patent estates and reduce legal review cycles.

Medicinal chemists often optimize for potency first, leading to late-stage failures due to poor ADMET or physicochemical properties. The workflow implements a formalized Multi-Parameter Optimization (MPO) agent that balances potency, selectivity, predicted ADMET, and developability scores based on a configurable target product profile. This brings objective, data-driven trade-off analysis to lead optimization, improving the overall quality and probability of success for selected candidates.

Traditional design decisions are documented in disparate notebooks and meetings, losing rationale and creating reproducibility challenges. The workflow orchestrates all steps—from scaffold input to final candidate list—within a versioned, auditable pipeline. Every design hypothesis, transformation rule, model prediction, and selection score is logged, creating a defensible data trail for project reviews, regulatory inquiries, and AI model governance, turning design into a traceable operational process.

The largest inefficiency is the manual handoff between design ideation and synthesis execution. This workflow closes the loop by outputting structured, machine-readable synthesis plans—including suggested routes, reagent lists, and predicted protocols—that can feed directly into electronic lab notebooks (ELNs) or robotic synthesis platforms. By automating the translation of digital designs into actionable lab instructions, it accelerates the DMTA cycle, turning weeks of planning into days of execution.

This specialized agent applies graph-based transformations and fragment libraries to a promising lead scaffold, generating thousands of novel analogs. It uses rule-based and generative AI methods to explore chemical space while adhering to medicinal chemistry principles and IP boundaries, ensuring each proposed structure maintains the core pharmacophore but explores new vectors for improvement.

The orchestration layer aggregates predictions for potency, selectivity, ADMET, and physicochemical properties into a unified, weighted MPO score for each candidate. This engine applies customizable business rules and target product profiles to rank analogs objectively, replacing subjective debate with data-driven prioritization and surfacing compounds with the highest overall probability of success.

Before final candidate selection, this agent performs retrosynthesis analysis to predict synthetic feasibility. It checks reagent availability against internal inventory and vendor catalogs, scores routes for complexity and cost, and outputs draft synthesis instructions. This grounds virtual designs in practical chemistry, preventing the advancement of unrealistic targets and accelerating the handoff to synthesis teams.

A critical governance component that screens all generated analogs against global patent databases and internal IP. This layer flags potential freedom-to-operate (FTO) risks early, guiding the design agent away from infringing chemical space. It creates an audit trail for IP due diligence, helping to protect novel series and identify white space for patent filing.

The workflow is designed for integration with Electronic Lab Notebooks (ELNs) and assay data management systems. It submits prioritized synthesis lists, ingests experimental results from biochemical and property assays, and uses that new data to retrain predictive models. This creates a true Design-Make-Test-Analyze (DMTA) cycle, continuously improving the AI's recommendations based on real-world feedback.

Built on frameworks like LangGraph or CrewAI for agent coordination, the workflow connects cloud HPC for simulations, chemical databases (e.g., internal registry, ChEMBL), and lab informatics systems (e.g., Benchling, Dotmatics). Deployment involves containerized agents, secure API gateways, and a dashboard for medicinal chemists to review ranked candidates, override scores, and approve the next batch for synthesis.